Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China

書誌詳細
出版年:	PLoS ONE
主要な著者:	Chaoneng He, Xiufang Mi, Gaoqi Xu, Xinglu Xu, Wenxiu Xin, Like Zhong, Junfeng Zhu, Qi Shu, Luo Fang, Haiying Ding
フォーマット:	論文
言語:	英語
出版事項:	Public Library of Science (PLoS) 2024-01-01
オンライン･アクセス:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095747/?tool=EBI

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. 著者: Chaoneng He, Xiufang Mi, Gaoqi Xu, Xinglu Xu, Wenxiu Xin, Like Zhong, Junfeng Zhu, Qi Shu, Luo Fang, Haiying Ding

出版年 PLoS ONE (2024-01-01)

全文の入手

論文